

**Client:** Chi Med  
**Source:** The Week (Main)  
**Date:** 01 March 2014  
**Page:** 51  
**Reach:** 191401  
**Size:** 249cm2  
**Value:** 4295.25

## Who's tipping what

### The week's best buys

#### **Hutchison China MediTech**

*Investors Chronicle*

Sales in Chi-Med's drug development business have doubled, underpinned by big-pharma partnerships and a booming healthcare division. Results confirm that the growth story has further to go. Buy. 698p.

#### **Mondi**

*The Daily Telegraph*

Boosted by the trend for online shopping and convenience foods, the packaging giant has been upgrading its paper mills to fulfil demand from emerging economies. Profits are increasing and the dividend is rising. Buy. £10.52.

#### **Plus500**

*The Daily Telegraph*

Shares in the Aim-listed online trading platform have doubled as revenues and profits rocket. It is risky, but it generates a lot of cash, has a generous dividend policy and is delivering decent growth. Buy. 425p.

#### **Telecom Plus**

*Shares*

The utility group's success in acquiring customers and convincing them to take all five services – gas, electricity, home phone, broadband and mobile – should continue to produce bumper profits, earnings and cash flow. Buy. £18.35.

#### **Travis Perkins**

*Investors Chronicle*

The market-leading builders' merchant, which owns retail chains Wickes and Tile Giant, is well placed to benefit from the improving economy, the house-building uptick and continued low interest rates. Buy. £19.31.

#### **WH Ireland**

*The Mail on Sunday*

The stockbroker is flourishing under new CEO Richard Killingbeck; both corporate and private client divisions are expanding organically and through acquisitions, gaining new clients and increasing profits. Buy. 94p.

### ...and some to sell

#### **Capita Group**

*The Daily Telegraph*

Despite major new contracts, the outsourcing giant's falling profit margins remain worrying ahead of the hiatus surrounding spending decisions around a general election. Take profits on an 8% rise. Sell. £10.62.

#### **Coca-Cola Hellenic Bottling Company**

*Shares*

Coca-Cola's European bottler has a wide geographical footprint and strong branded products. But currency volatility, and exposure to struggling economies like Italy and Greece, make its rating hard to justify. Sell. £15.84.

#### **Galliford Try**

*London Evening Standard*

The housebuilder has increased its interim dividend following "record" half-year results, but Panmure Gordon is concerned that shares – at 130% net asset value – are too expensive. The broker names a £10.17 target price. Sell. £11.47.

#### **Genus**

*London Evening Standard*

Revenue growth at the cattle and pig sperm firm – which majors on exports to emerging markets – may be restricted by currency difficulties, warns Panmure Gordon, which has reiterated its sell rating. Sell. 1200p.

#### **Latchways**

*Investors Chronicle*

High operational gearing has caused a revenue shortfall, resulting in another profit warning at Latchways, which provides fall-protection equipment. Given the uncertainty over earnings, shares are over-rated. Sell. £11.15.

#### **New World Resources**

*Investors Chronicle*

The beleaguered coal miner has suffered rising costs, falling production, tumbling coal prices and sliding revenues. Not even cost-cutting can fix its "rapidly deteriorating balance sheet". Sell. 46p.